View the characteristics of the SJLIFE cohort relative to the CCSS cohort. The table was last updated May 21, 2019.

Characteristics of SJLIFE Cohort Relative to the CCSS Cohort

Characteristics

SJLIFE Cohort (n=9556)

Dx 1962-2012

CCSS Cohort (n=25,665)

Dx 1970-99

Sex

Female

45.3%

46.5%

Male

54.7%

53.5%

Race Ethnicity

White not Hispanic

76.6%

79.4%

Black not Hispanic

16.9%

6.2%

American Indian/Alaska Native

0.1%

<1.0%

Asian Pacific Islander

0.5%

0.5%

Hispanic

4.1%

7.8%

Other

1.6%

3.3%

Unknown

0.2%

1.1%

Primary Diagnosis

Leukemia

32.6%

30.7%

Lymphoma

15.1%

20.3%

CNS tumor

17.4%

17.5%

Embryonal tumors

16.8%

16.5%

Bone and Soft Tissue Sarcoma

11.8%

15.0%

Carcinoma

1.6%

0.0%

Other

4.7%

0.0%

Age at Diagnosis (yrs)

0-4

42.1%

39.7%

5-9

22.7%

22.5%

10-19

34.2%

36.1%

20+

1.0%

1.7%

Years of Diagnosis

1958-1969

2.7%

0.0%

1970-1979

11.9%

25.8%

1980-1989

20.3%

39.2%

1990-1999

24.1%

35.0%

2000+

41.0%

0.0%

Treatment Modalities

Chemo + RT

42.7%

42.2%

Chemo

40.3%

31.8%

RT

10.2%

8.1%

No Chemo/No RT

6.7%

8.8%

  

Geographic distribution of SJLIFE participants

The SJLIFE cohort is geographically diverse with the largest proportion of participants from the mid-South region of the United States.

Map of geographic distribution of SJLIFE participants

  

Recruitment status of SJLIFE

As of February 1, 2019, for survivors where attempts to contact have been initiated, 80.4% (5753/7152) have been successfully enrolled and 87.2% have enrolled or have confirmed their interest in participating. Of all eligible survivors who are alive, 68.8% (5753/8363) have thus far been enrolled and 74.6% have enrolled or confirmed their interest in participating.

Pie chart of distribution of pediatric cancers

  

Cohort Recruitment Summary

Survivor participants who have completed their baseline clinical assessment are invited to return for subsequent systematic evaluations at a minimum of every 5 years. As of February 1, 2019: 47% (2257/4760) of survivors who have completed a baseline clinical assessment have returned for one or more subsequent follow-up assessments.

  

Distribution of Pediatric Cancers

SJLIFE includes all pediatric hematological and solid malignancies.

Pie chart of distribution of pediatric cancers

  

Monthly New Survivor and Control Enrollments

Among 5-year survivors in the expanded eligible cohort, we have recruited 3807 participants (averaging 89 survivor registrations per month1). In addition, 629 community controls have completed on-campus clinical evaluations.

SJLIFE UU01 Cohort Expansion bar graphs